Decoding Hypertension Through Primary Aldosteronism

HomeCirculationVol. 147, No. 14Decoding Hypertension Through Primary Aldosteronism No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextDecoding Hypertension Through Primary Aldosteronism Braxton D. Mitchell, PhD, MPH and Hilary B. Whitlatch, MD Braxton D. MitchellBraxton D. Mitchell Correspondence to: Braxton D. Mitchell, PhD, MPH, University of Maryland Medicine, 670 W Baltimore St, MSTF 302, Baltimore, MD 21201. Email E-mail Address: [email protected] https://orcid.org/0000-0003-4920-4744 Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore (B.D.M., H.B.W.). Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, MD (B.D.M.). Search for more papers by this author and Hilary B. WhitlatchHilary B. Whitlatch https://orcid.org/0000-0002-5770-6544 Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore (B.D.M., H.B.W.). Search for more papers by this author Originally published3 Apr 2023https://doi.org/10.1161/CIRCULATIONAHA.123.064028Circulation. 2023;147:1110–1111This article is a commentary on the followingGenetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies"Decoding Hypertension Through Primary Aldosteronism." Circulation, 147(14), pp. 1110–1111FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 1111.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Braxton D. Mitchell, PhD, MPH, University of Maryland Medicine, 670 W Baltimore St, MSTF 302, Baltimore, MD 21201. Email [email protected]umaryland.eduReferences1. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.Lancet Diabetes Endocrinol. 2018; 6:41–50. doi: 10.1016/S2213-8587(17)30319-4CrossrefMedlineGoogle Scholar2. Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, Miller BS, Giordano TJ, Tomlins SA, Rainey WE. Targeted molecular characterization of aldosterone-producing adenomas in White Americans.J Clin Endocrinol Metab. 2018; 103:3869–3876. doi: 10.1210/jc.2018-01004CrossrefMedlineGoogle Scholar3. Naito T, Inoue K, Sonehara K, Baba R, Kodama T, Otagaki Y, Okada A, Itcho K, Kobuke K, Kishimoto S, et al. Genetic risk of primary aldosteronism and its contribution to hypertension: a cross-ancestry meta-analysis of genome-wide association study.Circulation. 2023; 147:1097–1109. doi: 10.1161/CIRCULATIONAHA.122.062349LinkGoogle Scholar4. Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker KL, Hammer GD. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex.Development. 2008; 135:2593–2602. doi: 10.1242/dev.021493CrossrefMedlineGoogle Scholar5. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrançois-Martinez AM, et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.Hum Mol Genet. 2010; 19:1561–1576. doi: 10.1093/hmg/ddq029CrossrefMedlineGoogle Scholar6. Gomez-Sanchez CE, Kuppusamy M, Gomez-Sanchez EP. Somatic mutations of the ATP1A1 gene and aldosterone-producing adenomas.Mol Cell Endocrinol. 2015; 408:213–219. doi: 10.1016/j.mce.2014.12.004CrossrefMedlineGoogle Scholar7. Fernandes-Rosa FL, Daniil G, Orozco IJ, Göppner C, El Zein R, Jain V, Boulkroun S, Jeunemaitre X, Amar L, Lefebvre H, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism.Nat Genet. 2018; 50:355–361. doi: 10.1038/s41588-018-0053-8CrossrefMedlineGoogle Scholar8. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.Lancet. 2021; 398:957–980. doi: 10.1016/S0140-6736(21)01330-1CrossrefMedlineGoogle Scholar9. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.Nat Genet. 2018; 50:1412–1425. doi: 10.1038/s41588-018-0205-xCrossrefMedlineGoogle Scholar10. Funder JW, Carey RM. Primary aldosteronism: where are we now? Where to from here?Hypertension. 2022; 79:726–735. doi: 10.1161/HYPERTENSIONAHA.121.18761LinkGoogle Scholar11. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study.Ann Intern Med. 2020; 173:10–20. doi: 10.7326/M20-0065CrossrefMedlineGoogle Scholar12. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.J Clin Endocrinol Metab. 2004; 89:1045–1050. doi: 10.1210/jc.2003-031337CrossrefMedlineGoogle Scholar13. Williams TA, Reincke M. Non-invasive detection of a common, surgically correctable form of hypertension.Nat Med. 2023; 29:31–32. doi: 10.1038/s41591-022-02083-9CrossrefMedlineGoogle Scholar14. Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism.Eur J Nucl Med Mol Imaging. 2020; 47:2656–2665. doi: 10.1007/s00259-020-04722-0CrossrefMedlineGoogle Scholar15. Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, Argentesi G, O’Toole SM, Matson M, Koo B, et al. [(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial.Nat Med. 2023; 29:190–202. doi: 10.1038/s41591-022-02114-5CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesGenetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association StudiesTatsuhiko Naito, et al. Circulation. 2023;147:1097-1109 April 4, 2023Vol 147, Issue 14 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.064028PMID: 37011072 Originally publishedApril 3, 2023 KeywordsEditorialshyperaldosteronismhypertensionPDF download Advertisement SubjectsGenetic, Association StudiesPrecision Medicine